EUCTR2014-005377-36-FI进行中（未招募）1 期
An 8-week, single centre, randomized, parallel-group, double-blind, placebo controlled phase IV study to evaluate Dapagliflozin 10 mg once daily effects on insulin resistance in subjects with type 2 diabetes mellitus.
AstraZeneca AB, R&D Mölndal0 个研究点目标入组 32 人开始时间: 2015年1月20日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study subjects should fulfil the following criteria:
- •1) Provision of signed informed consent prior to any study specific procedures.
- •2) Female or male aged 35 to 70 years inclusive with suitable veins for cannulation or repeated venepuncture
- •3) Type 2 Diabetes mellitus defined as HbA1c of = 6.5% and = 10.5%.
- •4) Be on stable (= 3 months) T2D treatment with
- •either metformin, sulphonylurea or dipeptidyl peptidase-4 inhibitors (DPP-IV) alone
- •metformin in combination with sulphonylurea or DPP-IV
- •5) Have a body mass index (BMI) (measured as body weight (kg)/(height (m))2) = 40 kg/m2.
- •6) Female subjects must be of non-childbearing potential, meeting at least one of the following criteria:
- •a) Hysterectomized females
- •b) Postmenopausal women, defined as women who have not had a menstrual period within 1 year
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1) Involvement in the planning and/or conduct of the study.
- •2) Previous enrolment in the present study.
- •3) Participation in another clinical study with an IP during the last 3 months prior to Visit 1.
- •4) Has any condition that is contraindicated with MRI such as, but not limited to, having a pacemaker or claustrophobia.
- •5) History of or presence of (as found at Visit 1) any clinically significant disease, disorder or condition which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject’s ability to participate in the study.
- •6) Volume depleted patients. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.
- •7) Recent Cardiovascular Events in a patient:
- •- Acute Coronary Syndrome (ACS) within 2 months prior to enrolment
- •- Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment
- •- Acute Stroke or Transient Ischemic Attack (TIA) within two months prior to enrolment
- •- Less than two months post coronary artery revascularization
- •8) Congestive heart failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure.
- •Note: eligible patients with congestive heart failure, especially those who are on diuretic therapy, should have careful monitoring of their volume status throughout the study.
- •9) Blood pressure at enrolment: Systolic BP =165 mm Hg and/or diastolic BP =100 mm Hg
- •10)Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of the first administration of IP.
- •11)On insulin, GLP-1 or other oral antidiabetic drug treatment (metformin, sulphonylurea or DPP-IV, or a combination of metformin with sulphonylurea or DPP-IV allowed) or using other medications known to affect glucose metabolism.
- •12)Any clinically significant abnormalities in physical examination, Electrocardiography (ECG) or clinical chemistry results at as judged by the investigator. The following specific exclusion criteria apply to the selected Clinical Chemistry results:
- •a) Creatinine clearance <60mL/min (estimated with Cockroft-Gault formula).
- •b) Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN.
- •c) Total bilirubin (TB) >2.0 mg/dL (34.2 µmol/L).
- •13) Recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse is defined as >14 drinks per week (1 drink= 35 cl beer, 14 cl wine or 4 cl hard liquor) or as judged by the investigator.
- •14) Body weight loss greater than 5% within 3 months prior to Visit 1.
- •15)Any other condition the investigator believe would interfere with the subject’s ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.
- •16) Plasma donation within one month of Visit 2 or any blood donation/blood loss > 500 mL during 3 months prior to Visit 2.
- •17) Previous PET scan
研究者
相似试验
招募中
1 期
Feasibility study of VR digital therapies in MDD patientsMajor Depressive Disorder (MDD)Depressive DisorderVR treatmentMajor Depressive DisorderTCTR20230824007ational Center for Global Health and Medicine (NCGM)100
进行中（未招募）
不适用
An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer' s disease. - LEADe Lipitor's Effect on Alzheimer DementiaAlzheimer DiseaseEUCTR2004-002007-33-ATPfizer Inc.600
进行中（未招募）
1 期
Combination treatment with dapagliflozin and exenatide to investigate the effect of weight loss in subjects with obesity compared to placebo.Obesity defined as body mass index (BMI) 30-45 kg/m2Obesity related metabolic disordersMedDRA version: 18.0Level: LLTClassification code 10029885Term: Obesity, unspecifiedSystem Organ Class: 100000004861EUCTR2014-003432-39-SEDept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
进行中（未招募）
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertensionEUCTR2006-000774-70-GBovartis Pharma Services AG2,252
进行中（未招募）
不适用
An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodipine, and HCTZ/amlodipine in patients with moderate to severe hypertensioHypertensionEUCTR2006-000774-70-SEovartis Pharma Services AG2,252